Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.

• Status: Completed
• Trial end date: 1969-12-31

Summary

2 different treatment schedules may be used for neoadjuvant chemotherapy in breast cancer using adriamycin, cyclophosphamide and taxotere. The most optimal sequence- concurrent or sequential- is however unclear. The aim of the study is to compare the efficacy and tolerability of neoadjuvant chemotherapy with AC followed by T(adriamycin, cyclophosphamide, taxotere) versus TAC ( with upfront T) in patient with large resectable or locally advanced breast cancer.

• Phase: Phase 3

Details

• Lead Sponsor: Radboud University
• Collaborators: Amgen; Sanofi
• Treatments: Cyclophosphamide; Docetaxel; Doxorubicin; Liposomal doxorubicin